Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma..
10.4046/trd.2007.62.5.432
- Author:
Seung Min LEE
1
;
Soon Young KO
;
Tae Ho SEO
;
Jung Hyun LEE
;
Seung Oh CHOI
;
Jeong Geun LEE
;
Wan Seop KIM
;
Tae Hoon LEE
;
Gwang Ha YOO
;
Kye Young LEE
Author Information
1. Department of Internal Medicine, College of Medicine, Konkuk University, Seoul, Korea. kyleemd@kuh.ac.kr
- Publication Type:Case Report
- Keywords:
Malignant pleural mesothelioma;
Pemetrexed;
Cisplatin
- MeSH:
Adenocarcinoma;
Cisplatin;
Cytotoxins;
Drug Therapy, Combination*;
Humans;
Maintenance Chemotherapy;
Mesothelioma*;
Prognosis;
Tumor Burden;
Pemetrexed
- From:Tuberculosis and Respiratory Diseases
2007;62(5):432-436
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Malignant pleural mesothelioma (MPM) is a rare tumor that is difficult to clearly distinguish from an adenocarcinoma but usually has a poor prognosis. Numerous cytotoxic agents have been used in the primary treatment of MPM with limited success. A complete response is unusual and a partial response occurs in less than one-third of patients. Recently, a phase III trial showed that a combination of pemetrexed with cisplatin resulted in a significantly higher response rate and median survival time than with cisplatin alone. We encountered a case of a dramatic tumor response to pemetrexed/cisplatin combination chemotherapy in patients with MPM, which was resistant to the 1st-line gemcitabine/cisplatin therapy. After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had decreased dramatically with complete symptom relief. There was no chemotherapy-related toxicity or scheduled violation. The patient is under maintenance chemotherapy with the same regimen.
